General Information of Drug (ID: DMQGUMN)

Drug Name
PMID25991433-Compound-J1 Drug Info
Cross-matching ID
PubChem CID
25123232
TTD Drug ID
DMQGUMN

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
GBL-310 DM2IFJQ Keratosis ED56 Phase 2 [2]
LTT462 DM94E6W Solid tumour/cancer 2A00-2F9Z Phase 1 [3]
PF-07799544 DMAO10K Aggressive cancer 2A00-2F9Z Phase 1 [4]
PMID25991433-Compound-L2 DM58UO9 N. A. N. A. Patented [1]
PMID25991433-Compound-L3 DM3LWUR N. A. N. A. Patented [1]
Bidentate ligands of Markush derivative 2 DM2QNMC N. A. N. A. Patented [5]
Bidentate ligands of Markush derivative 1 DMB08D3 N. A. N. A. Patented [5]
PMID25991433-Compound-Q1 DMEMSB2 N. A. N. A. Patented [1]
PMID25991433-Compound-C3 DMSKWBE N. A. N. A. Patented [1]
PMID25991433-Compound-J6 DMOWULJ N. A. N. A. Patented [1]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Mitogen-activated protein kinase (MAPK) TTVOE6D NOUNIPROTAC Inhibitor [1]

References

1 c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
2 WO patent application no. 2010,0456,51, Methods for analyzing drug response.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
5 Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676.